Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Related SNY
Impax to Sell Authorized Generic Renvela - Analyst Blog
Prestige Brands Gains on Product Acquisition News - Analyst Blog
Novo Nordisk Upgraded to 'Buy' (Fox Business)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News

 

Most Popular

Related Articles (SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free